{"id":"NCT00368277","sponsor":"Novartis Pharmaceuticals","briefTitle":"A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","officialTitle":"A 36 Week Randomized, Double-blind, Parallel Group, Multi-center, Active-controlled, Optional Titration Study Comparing an Aliskiren-based Regimen to a Ramipril-based Regimen in Patients â‰¥ 65 Years Old With Systolic Essential Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2006-09","primaryCompletion":"2008-02","completion":"2008-02","firstPosted":"2006-08-24","resultsPosted":"2011-03-25","lastUpdate":"2011-03-25"},"enrollment":901,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hypertension"],"interventions":[{"type":"DRUG","name":"Aliskiren","otherNames":[]},{"type":"DRUG","name":"Ramipril","otherNames":[]},{"type":"DRUG","name":"Hydrochlorothiazide","otherNames":[]},{"type":"DRUG","name":"Amlodipine","otherNames":[]}],"arms":[{"label":"Aliskiren-based regimen","type":"EXPERIMENTAL"},{"label":"Ramipril-based regimen","type":"ACTIVE_COMPARATOR"}],"summary":"Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.","primaryOutcome":{"measure":"Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12","timeFrame":"Baseline and Week 12","effectByArm":[{"arm":"Aliskiren Based Treatment Regimen","deltaMin":-13.96,"sd":0.754},{"arm":"Ramipril Based Treatment Regimen","deltaMin":-11.64,"sd":0.759}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["33089502"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":452},"commonTop":["Headache","Cough","Dizziness","Upper respiratory tract infection","Diarrhoea"]}}